(2023) conducted a preliminary study to assess the feasibility of utilizing a CD133-specific CAR-T cell system to deliver locally PD-1 blocking scFv as a monotherapy for advanced hepatocellular carcinoma (HCC). Here, PROM1 is linked to hepatocellular carcinoma.